The Semaglutide Battle: Why Drl Won the Right to Manufacture Despite Novo’s Patent

On 2 nd  December 2025, the Delhi High Court declined to grant an interim injunction restraining Dr. Reddy’s Laboratories from manufacturing semaglutide in India for export, notwithstanding Novo Nordisk’s assertion of infringement of Indian patent IN 262697 (IN’697). The Court’s order, rendered at the interlocutory stage, did not adjudicate the final validity of the patent but turned on the application of settled principles governing interim relief under Indian patent law. The dispute is...